Try our mobile app

NEW DATA FURTHER REINFORCE EFFICACY OF TEZSPIRE™ (TEZEPELUMAB-EKKO) IN A BROAD POPULATION OF SEVERE ASTHMA PATIENTS

Published: 2022-02-26 16:45:00 ET
<<<  go to AMGN company page

Analyses From NAVIGATOR and PATHWAY Trials Presented at the 2022 AAAAI Annual Meeting

THOUSAND OAKS, Calif., Feb. 26, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a pooled post-hoc analysis of the pivotal NAVIGATOR Phase 3 and PATHWAY Phase 2b trials showed TEZSPIRE™ (tezepelumab-ekko) demonstrated reductions in the annualized asthma exacerbation rate (AAER) across biomarker subgroups of patients with severe asthma.1 These findings support the role of TEZSPIRE as a first-in-class treatment for a broad population of people living with severe asthma, irrespective of biomarker levels.1

In the pooled analysis, TEZSPIRE, when added to standard of care (SoC), reduced asthma exacerbations in patients, irrespective of baseline blood eosinophil counts, demonstrating consistent efficacy with a 71% (≥300 cells per microliter), 48% (